|
|
Blood, 15 September 2005, Vol. 106, No. 6, pp. 2206-2214.
Prepublished online as a Blood First Edition Paper on June 7, 2005; DOI 10.1182/blood-2005-01-0062.
Previous Article | Next Article 
Submitted January 7, 2005
Accepted May 5, 2005
TGF in allogeneic stem cell transplantation: Friend or foe?
Tatjana Banovic, Kelli P MacDonald, Edward S Morris, Vanessa Rowe, Rachel Kuns, Alistair Don, Jane Kelly, Steven Ledbetter, Andrew D Clouston, and Geoffrey R Hill*
The Queensland Institute of Medical Research, Brisbane, QLD, Australia
The Queensland Institute of Medical Research, Brisbane, QLD, Australia; Department of Stem Cell Transplantation, Royal Brisbane Hospital, Brisbane, QLD, Australia
Genzyme Corporation, Framingham, MA, USA
Department of Pathology, University of Queensland, Brisbane, QLD, Australia
* Corresponding author; email: Geoff.Hill{at}qimr.edu.ai.
Donor treatment with G-CSF attenuates the ability of donor T cells to induce acute GVHD (aGVHD) but increases the severity of chronic GVHD (cGVHD). We investigated the role of the regulatory cytokine TGF in this paradox in well established murine models of acute and chronic GVHD where recipients are transplanted with splenocytes from donors treated with G-CSF. Neutralization of TGF after stem cell transplantation (SCT) significantly increased aGVHD and the concurrent prevention of IL-10 production further exaggerated this effect. Early following SCT, donor T cells were the predominant source of TGF and were able to attenuate aGVHD in a TGF -dependant fashion. Whilst the neutralization of TGF augmented the proliferation and expansion of donor T cells after SCT, it paradoxically impaired cellular cytotoxicity to host antigens and associated graft-versus-leukemia (GVL) effects. In cGVHD, neutralization of TGF from day 14 after SCT attenuated histopathology and CD11b+ mononuclear cells infiltrating sclerodermatous skin produced 50-fold more TGF than corresponding T cells. Thus, while the production of TGF by donor T cells early after transplantation attenuates aGVHD and is required for optimal GVL, the production of TGF late after SCT is preferentially from mononuclear cells and mediates cGVHD. These data have important implications for the timing of therapeutic TGF neutralization to prevent cGVHD after allogeneic SCT.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
N. Matsuno, A. Wake, N. Uchida, K. Ishiwata, H. Araoka, S. Takagi, M. Tsuji, H. Yamamoto, D. Kato, Y. Matsuhashi, et al.
Impact of HLA disparity in the graft-versus-host direction on engraftment in adult patients receiving reduced-intensity cord blood transplantation
Blood,
August 20, 2009;
114(8):
1689 - 1695.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Banovic, K. A. Markey, R. D. Kuns, S. D. Olver, N. C. Raffelt, A. L. Don, M. A. Degli-Esposti, C. R. Engwerda, K. P. A. MacDonald, and G. R. Hill
Graft-versus-Host Disease Prevents the Maturation of Plasmacytoid Dendritic Cells
J. Immunol.,
January 15, 2009;
182(2):
912 - 920.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Kanter, S. Y. Khan, M. Kelher, L. Gore, and C. C. Silliman
Oncogenic and Angiogenic Growth Factors Accumulate during Routine Storage of Apheresis Platelet Concentrates
Clin. Cancer Res.,
June 15, 2008;
14(12):
3942 - 3947.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Fujii, G. Cuvelier, K. She, S. Aslanian, H. Shimizu, A. Kariminia, M. Krailo, Z. Chen, R. McMaster, A. Bergman, et al.
Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group
Blood,
March 15, 2008;
111(6):
3276 - 3285.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. P. A. MacDonald, R. D. Kuns, V. Rowe, E. S. Morris, T. Banovic, H. Bofinger, B. O'Sullivan, K. A. Markey, A. L. Don, R. Thomas, et al.
Effector and regulatory T-cell function is differentially regulated by RelB within antigen-presenting cells during GVHD
Blood,
June 1, 2007;
109(11):
5049 - 5057.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Sakoda, D. Hashimoto, S. Asakura, K. Takeuchi, M. Harada, M. Tanimoto, and T. Teshima
Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease
Blood,
February 15, 2007;
109(4):
1756 - 1764.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Rowe, T. Banovic, K. P. MacDonald, R. Kuns, A. L. Don, E. S. Morris, A. C. Burman, H. M. Bofinger, A. D. Clouston, and G. R. Hill
Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation
Blood,
October 1, 2006;
108(7):
2485 - 2492.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. S. Morris, K. P. A. MacDonald, and G. R. Hill
Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?
Blood,
May 1, 2006;
107(9):
3430 - 3435.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Rutella, F. Zavala, S. Danese, H. Kared, and G. Leone
Granulocyte Colony-Stimulating Factor: A Novel Mediator of T Cell Tolerance
J. Immunol.,
December 1, 2005;
175(11):
7085 - 7091.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|